

SUPPLEMENTARY INFORMATION

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer

Andrew Woolston¹, Louise J Barber¹, Beatrice Griffiths¹, Oriol Pich², Nuria Lopez-Bigas^{2,3,4}, Nik Matthews⁵, Sheela Rao⁶, David Watkins⁶, Ian Chau⁶, Naureen Starling⁶, David Cunningham⁶, Marco Gerlinger^{1,6*}

- 1 Translational Oncogenomics Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.
- 2 Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.
- 3 Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain.
- 4 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
- 5 Tumour Profiling Unit, The Institute of Cancer Research, London SW3 6JB, UK.
- 6 Gastrointestinal Cancer Unit, The Royal Marsden Hospital, London SW3 6JJ, UK

Corresponding Author and Lead Contact:

Dr Marco Gerlinger, MD FRCP

Translational Oncogenomics Laboratory

The Institute of Cancer Research, London

237 Fulham Road

London SW3 6JB

United Kingdom

email: marco.gerlinger@icr.ac.uk

Tel: +44 207 153 5234

Supplementary Table 1. Patient characteristics of metastatic RAS/RAF wild type tumors from the Prospect-C trial and similar cohorts.

	Prospect C subset with paired BL and PD exome sequencing data	Entire Prospect C trial cohort (Cancer Cell. 2019 Jul 8; 36:35-50.e9)	Patients treated with cetuximab in the ASPECCT trial (Lancet Oncology 2014 May; 15:569-79)	Right sided colon cancer patients treated with cetuximab in the trial Eur J Cancer. 2015 Jul; 51:1405-14	Left sided colon cancer patients treated with cetuximab in the trial Eur J Cancer. 2015 Jul; 51:1405-14
	N=21	N=35	N=500	N=150	N=249
Median age (years)	67	66	61	64	64
Gender					
Male	66.7%	57.1%	64.0%	59.3%	61.9%
Female	33.3%	42.9%	36.0%	40.7%	38.2%
Site of Primary					
Left colon/rectum	66.7%	74.3%	data not available		62.4%
Right colon	33.3%	25.0%	data not available		37.6%
Lines of prior therapy					
1	9.5%	8.6%	data not available	7.3%	2.4%
2 or more	90.5%	91.4%	data not available	92.7%	97.6%

Supplementary Table 2. deconstructSigs assigned weights for BL prolonged benefit cases.

Signatures	C1005BL	C1007BL	C1014BL	C1018BL	C1020BL	C1024BL	C1025BL	C1026BL	C1027BL	C1030BL	C1037BL	C1044BL
SBS1	0.35	0.33	0.17	0.35	0.34	0.36	0.28	0.25	0.28	0.42	0.35	0.25
SBS3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SBS5	0.35	0.42	0.16	0.31	0.50	0.42	0.37	0.38	0.29	0.35	0.32	0.00
SBS6	0.00	0.07	0.24	0.10	0.00	0.07	0.01	0.00	0.04	0.00	0.00	0.00
SBS15	0.00	0.00	0.01	0.00	0.03	0.00	0.07	0.11	0.00	0.00	0.10	0.09
SBS17a	0.00	0.00	0.04	0.04	0.01	0.00	0.00	0.00	0.01	0.00	0.02	0.00
SBS17b	0.00	0.07	0.00	0.00	0.00	0.00	0.11	0.00	0.06	0.03	0.10	0.07
SBS35	0.14	0.11	0.12	0.00	0.12	0.08	0.16	0.00	0.00	0.03	0.00	0.14
SBS40	0.16	0.00	0.28	0.20	0.00	0.08	0.01	0.26	0.32	0.18	0.11	0.45
R2	0.88	0.91	0.88	0.92	0.87	0.84	0.90	0.88	0.81	0.92	0.90	0.80
MutationLoad	191	212	234	172	98	205	160	235	198	143	143	172